- Policy
- Hyaluronic acid eye drops, start to revise the standard
- by Lee, Tak-Sun Oct 11, 2023 05:36am
- The HIRA has started to revise the standards to limit the use of Hyaluronic acid sodium eye drops. It is known that the revision of standards will be completed as early as the end of the year, and will be implemented from next year. According to an industry example on the 10th, the HIRA has entered a review of the revision of the standards f
- Policy
- Tepmetko attempts reimb again in KOR
- by Lee, Tak-Sun Oct 10, 2023 05:27am
- Merck is reattempting reimbursement listing of its MET-targeted anticancer therapy ‘Tepmetko (tepotinib)’ in Korea. The drug was unable to pass the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review in February. The company voluntarily withdrew its reimbursement process at the time. The c
- Policy
- Will Leclaza also begin drug price negotiations soon?
- by Lee, Tak-Sun Oct 10, 2023 05:26am
- The expansion of reimbursement for Leclaza, a third-generation EGFR TKI non-small cell lung cancer treatment developed by Yuhan Corporation, as a first-line treatment will be discussed at the HIRA Pharmaceutical Reimbursement Evaluation Committee on the 12th. If the Pharmaceutical Reimbursement Evaluation Committee recognizes the adequacy of
- Policy
- Pfizer applies for reimb of its COVID-19 Tx Paxlovid
- by Lee, Tak-Sun Oct 6, 2023 05:36am
- Pfizer applied for the reimbursement of its COVID-19 treatment 'Paxlovid' in Korea. With the government planning to end the current free support system for COVID-19 treatments in the 1H next year, the company has begun the process of applying for reimbursement accordingly. According to the industry on the 5th, Pfizer Korea recently s
- Policy
- Reducing criminal liability for essential healthcare
- by Lee, Jeong-Hwan Oct 6, 2023 05:36am
- The ruling party proposed legislation to reduce criminal liability for doctors embroiled in medical malpractice suits while providing essential health services, and for the state and local governments to support and foster essential healthcare personnel. The legislation is in line with the Yoon Suk Yeol administration's policies to streng
- Policy
- Health plans expected to be implemented after NA audit
- by Lee, Jeong-Hwan Oct 5, 2023 05:27am
- The preferential drug price policy plan that reflects the value of new drugs and the 2nd comprehensive national health insurance plan, which the pharmaceutical and bio-industry are closely eyeing, is expected to be unveiled after the National Assembly audit this year. The amendment to the Instructions for the Biohealth Innovation Committe
- Policy
- Medical expenses exceed ₩1 trillion
- by Lee, Tak-Sun Oct 4, 2023 05:35am
- The number of lung cancer patients has steadily increased, and health insurance medical expenses exceeded 1 trillion won last year. The NHIS (Chairman Jeong Ki-seok) announced this by using health insurance treatment data to promote the status of health insurance treatment for lung cancer patients from 2018 to 2022. The number of patients tre
- Policy
- New pharmaceutical data protection system begins
- by Lee, Jeong-Hwan Oct 4, 2023 05:35am
- Legislation is being promoted to abolish the drug reexamination system, establish a separate legal basis for the drug data protection system, encourage research and development in the pharmaceutical industry, and strengthen the monopoly on the IMDs market. It also includes provisions to reduce the burden on pharmaceutical companies due to th
- Policy
- Legislation to prevent reverse-payment agreements
- by Lee, Jeong-Hwan Oct 4, 2023 05:35am
- Legislation is being promoted to eradicate the so-called 'generic reverse-payment agreements’ that prevent the launch of generic drugs by delaying or suspending the price cuts made on new drugs. If passed, the legislation will stipulate the reduction in the reimbursement price or suspension of reimbursement of drugs that took part in u
- Policy
- Myung-in & Hwan-in are launching Fycompa’s generics
- by Lee, Tak-Sun Sep 27, 2023 05:44am
- It is to launch early , and through this, the drug price was added 6% more than before. According to the industry on the 25th, Myungin and Hwanin will be reimbursed, respectively, on the 14th, when Fycompa material patent expires. It is launched on the market with a total of 6 dosages, and it is the first of the same ingredient in Korea. T
